share_log

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5

Benzinga ·  Nov 17, 2023 07:10

HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $3.75 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment